10 recruiting, 2 completed. 9 Phase 3, 3 Phase 1.
By phase and status
Follow KarX-EC: new trials by email Literature Review of KarX-EC trials Research Report on KarX-EC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder Phase 3 Recruiting 176 2026-10-06 2026-11-10
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder Phase 3 Recruiting 176 2026-10-06 2026-11-10
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability Phase 3 Recruiting 400 2026-04-07 2026-11-06
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo - Alzheimer Disease, Psychosis Phase 3 Recruiting 325 2026-03-25 2026-06-30
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) KarXT, KarX-EC - Alzheimer Disease, Agitation Phase 3 Recruiting 650 2025-12-02 2026-11-12
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) KarXT, KarX-EC, Placebo - Alzheimer's Disease Phase 3 Recruiting 586 2025-07-21 2026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease Phase 3 Recruiting 426 2025-07-16 2026-11-03
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease KarXT, KarX-EC, Placebo - Alzheimer's Disease Phase 3 Recruiting 586 2025-07-14 2026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer Disease Phase 3 Recruiting 426 2025-07-10 2026-11-06
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Trospium Chloride - Healthy Volunteers Phase 1 Recruiting 236 2025-06-27 2026-08-17
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders KarXT, KarX-EC - Psychiatric Disorders Phase 1 Completed 24 2025-04-29 2025-08-06
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants KarXT, KarX-EC, Placebo - Healthy Volunteers Phase 1 Completed 78 2024-10-01 2025-07-04
Conditions studied Alzheimer Disease (6) · Dementia (3) · Autism Spectrum Disorder (2) · Cognitive Dysfunction (2) · Psychomotor Agitation (2) · Autistic Disorder (1) · Mental Disorders (1) · Psychotic Disorders (1) · Schizophrenia (1)
Sponsors Bristol-Myers Squibb (10) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (2)
Countries United States (11) · Canada (6) · France (6) · Japan (6) · Poland (6) · Puerto Rico (6) · Romania (6) · Spain (6) · Argentina (5) · Australia (5) · Germany (5) · India (5) · United Kingdom (5) · Brazil (4) · Greece (4)
NIH funding 2025 (6)